Roche will fund projects like cancer biomarkers and pathology.
Roche is teaming up with the Swiss Federal Institute of Technology (ETH Zurich), the University of Zurich (UZH), and the University Hospital Zurich (USZ) to establish an external academic translational research center. The new hub will foster collaborations between Roche and academic researchers from the three Swiss institutions, in fields spanning pathology, dermatology, and inflammation, and potentially other diseases.
Roche scientists from both its diagnostics and pharmaceuticals divisions will work alongside the academic teams to define collaborative projects, with Roche providing initial financial support for 3–6 years. The first projects will include a biomarker survey on oncology drug patients, the development of RNA technology tools, and research related to pathways and assay development in pathology.
“External collaborations with academic institutions are at the core of our strategy and are fundamental to develop the next generation of treatments in areas of unmet medical need,” comments Jean Jacques Garaud, global head of Roche Pharma research and early development. “This partnership brings together high-caliber researchers, building on the full range of skills and expertise needed to develop new therapeutic and diagnostic solutions for patients.”